oxytocin/neurophysin I prepropeptideGenealiases: OT · OT-NPI · OXT-NPI
Q-omics provides the consensus-scored OXT profile across patient tissues and cancer cell-line models. OXT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, OXT is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, OXT RNA expression shows 11,133 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LIHC, and TGCT as cancer lineages where OXT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OXT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OXT survival associations across molecular data types. OXT RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OXT RNA expression–survival associations across cancer types. High OXT expression shows unfavorable associations in OV and SCLC, but favorable associations in KIRP, UCS, UVM and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for OXT RNA expression.
This table summarizes OXT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for OXT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OXT shows lower tumor expression in LIHC, KICH, KIRP and KIRC and higher tumor expression in LUAD and HNSC. The LIHC box plot shows higher OXT RNA expression in normal versus tumor tissue (log2 FC = −2.117, t-test p < 0.001).
This table shows molecular features associated with OXT in patient tissues and cancer cell lines. In patient samples, OXT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OXT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
